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Abstract
Intestinal epithelial cell derived alkaline phosphatase (IAP) dephosphorylates/
detoxifies bacterial endotoxin lipopolysaccharide (LPS) in the gut lumen. We
have earlier demonstrated that consumption of high-fat high-cholesterol con-
taining western type-diet (WD) significantly reduces IAP activity, increases
intestinal permeability leading to increased plasma levels of LPS and glucose
intolerance. Furthermore, oral supplementation with curcumin that increased
IAP activity improved intestinal barrier function as well as glucose tolerance.
To directly test the hypothesis that targeted increase in IAP would protect
against WD-induced metabolic consequences, we developed intestine-specific
IAP transgenic mice where expression of human chimeric IAP is under the
control of intestine-specific villin promoter. This chimeric human IAP con-
tains domains from human IAP and human placental alkaline phosphatase,
has a higher turnover number, narrower substrate specificity, and selectivity
for bacterial LPS. Chimeric IAP was specifically and uniformly overexpressed
in these IAP transgenic (IAPTg) mice along the entire length of the intestine.
While IAP activity reduced from proximal P1 segment to distal P9 segment in
wild-type (WT) mice, this activity was maintained in the IAPTg mice. Dietary
challenge with WD impaired glucose tolerance in WT mice and this intoler-
ance was attenuated in IAPTg mice. Significant decrease in fecal zonulin, a
marker for intestinal barrier dysfunction, in WD fed IAPTg mice and a corre-
sponding decrease in translocation of orally administered nonabsorbable
4 kDa FITC dextran to plasma suggests that IAP overexpression improves
intestinal barrier function. Thus, targeted increase in IAP activity represents a
novel strategy to improve WD-induced intestinal barrier dysfunction and glu-
cose intolerance.
Introduction
High-fat and high-cholesterol containing western type
diet (WD)-induced obesity remains one of the major
causes for the development of metabolic syndrome and
associated diseases such as type 2 diabetes (T2DM) and
coronary artery disease. In addition to changes in lipid
metabolism and excessive lipid accumulation, recent stud-
ies have also described direct effects of WD on gut micro-
biome and diet induced dysbiosis of gut flora is thought
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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to contribute to the development of metabolic diseases
(Sonnenburg and Sonnenburg 2014; Agus et al. 2016;
Martinez et al. 2017). Extensive research is underway to
define the changes in gut microbiome in several human
diseases in order to develop correlation between gut dys-
biosis and progress of these diseases (Selber-Hnatiw et al.
2017). However, how does this diet-induced dysbiosis
“communicates” with the host and brings about the sys-
temic metabolic changes is not completely defined. Under
physiological conditions, an intact intestinal lining not
only protects the host from direct interaction with patho-
genic gut bacteria (likely to increase during dysbiosis) but
also prevents the translocation of bacteria and bacterial
endotoxin (e.g., Lipopolysaccharide, LPS) to systemic cir-
culation. Altered gut mucosa with increased intestinal
permeability is associated with several chronic inflamma-
tory diseases and strong association between circulating
gut bacteria-derived LPS and metabolic diseases (such as
T2DM and atherosclerosis) has shifted the focus from
WD-induced changes in gut microbiota per se to release
of gut bacteria-derived products (e.g., LPS) into circula-
tion as the possible mechanism for the chronic inflamma-
tory state underlying the development of these diseases
(Nakarai et al. 2012). We demonstrated disruption of
intestinal barrier function by WD resulting in significant
release of bacterial LPS into the circulation of WD-fed
mice (Ghosh et al. 2014). Selective decontamination of
the gut or oral supplementation with curcumin signifi-
cantly improved the intestinal barrier function in WD fed
LDLR-/- mice resulting in decreased translocation of gut-
derived LPS into systemic circulation (Ghosh et al. 2014).
This led to improved glucose tolerance and attenuated
atherosclerosis without affecting plasma lipid profiles pro-
viding direct evidence that intestine is likely the “first line
of defense” against the metabolic consequences of WD
and targeted improvement of intestinal barrier function
may represent a novel strategy to attenuate WD-induced
metabolic diseases.
Intestinal barrier consists of multiple layers including:
(1) luminal intestinal alkaline phosphatase (IAP) that
dephosphorylates LPS to detoxify it; (2) the mucus layer
that provides a physical barrier preventing interactions
between gut bacteria and intestinal epithelial cells; (3) the
tight junctions between the epithelial cells that limit the
paracellular transport of bacteria and/or bacterial prod-
ucts to systemic circulation; and (4) the antibacterial pro-
teins secreted by the intestinal epithelial cells. The identity
of the component(s) of intestinal barrier affected by WD
or WD-induced gut dysbiosis remains currently unde-
fined. Furthermore, whether targeted improvement of
only one layer of the intestinal barrier would be sufficient
to prevent the translocation of bacterial-derived products
to systemic circulation has not been established.
In earlier studies, we demonstrated significant increase
in IAP activity following oral supplementation with cur-
cumin that also reduced WD-induced glucose intolerance
and atherosclerosis pointing to an important role for this
first layer of the intestinal barrier (Ghosh et al. 2014).
Intestinal alkaline phosphatase (IAP) is part of the lumi-
nal first line of defense and catalyzes the removal of one
of the two phosphate groups from the toxic lipid A moi-
ety of LPS producing monophosphoryl-LPS that still
binds to TLR4 but predominantly acts as an TLR4 antag-
onist (Bentala et al. 2002). Furthermore, Tan et al. (2015)
have recently described the inability of monophosphoryl-
LPS to appropriately bind to CD14 to facilitate TLR4
endocytosis and downstream signaling. Therefore, IAP is
central in maintaining the critical homeostasis that exists
between the host and the luminal microbial environment
(Bates et al. 2007) underscoring the importance of explor-
ing supplementation with exogenous IAP to alleviate
pathological conditions where host/microbial homeostasis
is perturbed such as colitis or chronic inflammation.
Consistently, Tuin et al. (2009) have reported a decrease
in IAP in patients with inflammatory bowel disease and
heat stable, chimeric human alkaline phosphatase is cur-
rently being evaluated as a protein therapeutic for gut
dysbiosis, inflammatory bowel disease, and acute kidney
injury (Kiffer-Moreira et al. 2014). However, IAP is an
acid-labile enzyme that completely loses its catalytic activ-
ity below pH 5.0 (Golotin et al. 2015) precluding effective
oral administration of an active enzyme although some
beneficial effects of oral administration of IAP (purified
calf intestinal alkaline phosphatase) to mice in drinking
water have been reported (Ramasamy et al. 2011; Kalian-
nan et al. 2013). To directly test the hypothesis that tar-
geted increase in IAP would protect against WD-induced
metabolic consequences, we developed intestine-specific
IAP transgenic mice expressing chimeric human IAP (de-
veloped by Kiffer-Moreira et al., 2014). This chimeric
human IAP contains domains from human IAP and
human placental alkaline phosphatase, displays greatly
increased heat stability, increased Zn2+ binding affinity,
increased transphosphorylation, a higher turnover num-
ber, narrower substrate specificity, and selectivity for bac-
terial LPS. Significant improvement of WD-induced
glucose intolerance was noted in intestine-specific IAP
transgenic mice.
Materials and Methods
Production and screening of transgenic mice
All animal protocols were approved by the Institutional
Animal Care and Use Committee at the Virginia Com-
monwealth University.
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DNA containing the open reading frame of the heat
stable, chimeric human intestinal alkaline phosphatase
(IAP) containing the catalytic domain of human placental
alkaline phosphatase that imparts enhanced catalytic effi-
ciency (Kiffer-Moreira et al. 2014) was synthesized by
Invitrogen. A C-terminal c-myc tag was added along with
5’ Xma I and 3’ Kpn I sites and the required Kozak box
and in-frame start codon at the 5’ end. This synthetic
sequence was cloned into pUC19 shuttle vector and the
Xma I/Kpn I fragment was subsequently cloned into Vil-
lin promoter driven transgenic expression vector
(12.4kbVillin-DATG, Plasmid #19358) obtained from
Addgene. The sequence of the chimeric transgene was
confirmed by sequencing in both directions. The villin-
IAP chimeric transgene was separated from the vector
sequence by digestion with Pme I, purified by agarose gel
electrophoresis, and 15.5 kb fragment was injected into
the pronuclei of fertilized mouse eggs obtained from
super-ovulated female mice (C57BL/6 or Balb-c/C57BL/6
hybrids). The injected eggs were surgically transferred to
oviducts of surrogate females. Offsprings were screened
for integration of the transgene by PCR amplification of
the tail DNA with the upstream primer sequence 50-C
AGACACTCTATGCCTGTGTGGAG-30 and the down-
stream primer sequence 50-GGAACCTTACTTCTGT
GGTGTGAC-30 to yield a 503-bp product. The transgenic
founder lines were maintained and propagated. Following
initial characterization, automated genotyping was per-
formed by Transnetyx, Inc. Transgenic (IAPTg) or non-
transgenic (WT – wild-type) littermates of both sexes
were used for all the studies and the number as well as
sex of mice included was therefore dependent on the litter
size.
Measurement of transgenic IAP expression
Nontransgenic (WT) and IAPTg littermates were eutha-
nized and liver, kidney as well as various regions of the
gastrointestinal tract were harvested. Tissues were
homogenized in RIPA buffer and total extracts were
subjected to SDS-PAGE followed by western blot analy-
ses. The presence of c-myc tag on transgenic IAP pro-
tein was identified using rabbit polyclonal anti-cmyc
primary antibody (Sigma-Aldrich, C3956). Total RNA
was prepared using RNeasy Kit (Qiagen) and specific
expression of transgenic IAP in different tissues was
monitored by SYBR-based real-time PCR using 5’ pri-
mer spanning the Kozak box and start codon (5’-
CGCCACATGCAGGGACC-3’) and 3’ primer spanning
the c-myc tag (5’-CCGAAATCAGCTTCTGCTCGTCGG-3’).
A standard curve was generated using serial dilution of
plasmid DNA and IAP copy number per lg total
RNA in different tissues was calculated as described
earlier (Zhao et al. 2007). Taqman gene expression
assays from Applied Biosystems were used to determine
the mRNA levels of endogenous IAP isoforms: AKP2
(Mm00475834_m1), AKP3 (Mm00475847_g1), AKP5
(Mm00475856_g1) and AKP6 (Mm01285814_g1).
Measurement of IAP enzyme activity
The complete gastrointestinal tract starting at the base
of the stomach to the tip of cecum was harvested. After
collecting duodenum and jejunum, the remaining length
of the intestine was cut into 9 equal segments. Tissues
were homogenized in 50 mM Tris-HCl buffer pH 7.5
containing 250 mmol/L sucrose. 0.2% Triton X-100 (v/
v) and protease inhibitors. The homogenates were cen-
trifuged at 10,000 x g for 10 min and postmitochon-
drial supernatant was used to determine IAP activity as
described earlier (de La Serre et al. 2010) using p-nitro-
phenylphosphate as substrate and expressed as mmoles/
h/mg total protein. Three different protein concentra-
tions and two time points were used to ensure
linearity.
Intraperitoneal glucose tolerance tests
Nontransgenic (WT) or IAPTg mice (littermates) at
10 weeks of age were fed a high-fat, high-cholesterol west-
ern type diet (WD, TD88137, Harlan Teklad) which con-
tained 21% fat, 0.15% cholesterol, and 19.5% casein by
weight with no sodium cholate for 16 weeks. After an
overnight fast, a single bolus of glucose (2 mg/g body
weight) was given intraperitoneally. Blood glucose levels
were determined by commercially available glucometer
using tail vein blood at 0, 15, 30, 60, 120 min.
Plasma analyses
Mice were fasted overnight and at the time of necropsy,
blood was collected by cardiac puncture and plasma was
frozen at 80°C until analyzed. Total plasma cholesterol
and triglyceride levels were determined using the Cobas
c311 automated chemistry analyzer, with reagents, calibra-
tors, and controls from Roche Diagnostics. Plasma LPS
levels were determined using Pierce LAL Chromogenic
Endotoxin Kit (Thermo Fisher) and IL-6 levels were mea-
sured by Ready-set-go ELISA kit from eBiosciences. Ali-
quots of undiluted plasma were also used to determine
total IAP activity as described above.
Translocation of FITC Dextran in vivo
Mice were orally gavaged with FITC-dextran 4 kDa
(600 lg/kg body weight) dissolved in deionized water
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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and plasma was collected after 4 h. Using three aliquots
of plasma in duplicate, FITC fluorescence (excitation
488 nm and emission 518 nm) was measured using Per-
kin Elmer Victor three plate reader and concentration
of FITC in plasma determined using a standard curve
and expressed as ng/lL of plasma.
Fecal analyses
Feces were collected over a period of 24 h from mice fed
WD for 16 weeks. Following vacuum drying in a dessica-
tor, dried feces was powdered using glass pestle and mor-
tar and the powder stored at 20°C until analyzed. Fecal
analyses were performed by Salveo Diagnostics laboratory
on a fee for service basis. For determining fecal IAP activ-
ity, dried feces was homogenized in water, centrifuged
and the supernatant used for IAP activity measurement.
FACS analyses of intestinal macrophages
At the time of euthanasia, one inch pieces of ileum and
colon were collected, cleaned of any luminal contents and
~50 mg tissue piece was enzymatically digested to prepare
single cell suspension as described earlier (Bie et al. 2011).
Isolated cells were re-suspended in FACS buffer containing
Fc block and incubated with fluorescently labeled antibod-
ies for 20 min at 4°C. After washing, 50,000 FITC-labeled
counting beads were added to each sample and analyzed
by flow cytometry (BD Biosciences, Canto II) with stop-
ping gate set to count 10,000 beads. The data were ana-
lyzed using FlowJO (Tree Star Inc.) software. The
following antibodies were used: Antimouse CD45-PE
(leukocytes), antimouse CD11b-PerCP-Cy5.5 (macro-
phages) antimouse Ly6C-APC and the respective isotype
controls (all antibodies were obtained from eBiosciences).
Statistical analyses
Comparison between two groups was performed using
Student’s t-test and P < 0.05 was considered significant.
One-way ANOVA with Bonferroni post hoc correction
was used for multiple comparisons and details are
included in Figure legends.
Results
Characterization of IAPTg mice
IAPTg mice were identified by PCR amplification of tail
DNA. One founder line in C57BL/6 background and one
in Balb-c/C57BL/6 hybrid background were obtained.
Both transgenic founder lines were analyzed for tissue dis-
tribution of IAP. Similar expression profiles were
obtained with both lines, and data for the C57BL/6 foun-
der line is shown in Figure 1. While some expression of
IAP transgene, as identified by c-myc tag, was seen in
liver and kidney, significantly higher expression was seen
in the duodenum, jejunum, ileum, and colon (Fig. 1A)
consistent with the reported use of this Villin promoter
construct (Madison et al. 2002). In accordance with the
observed protein expression, higher transgenic IAP mRNA
levels were observed in tissues from IAPTg mice com-
pared to nontransgenic (WT) mice (Fig. 1B). These data
confirm the successful development of intestine-specific
IAP transgenic mice. Genetic deletion of the major
intestinal isoform, AKP3, led to a compensatory increase
in the expression of other isoform (AKP6) resulting in no
apparent change in total IAP activity (Narisawa et al.
2007). To evaluate the effects of transgenic overexpression
of IAP on the expression of endogenous isoforms, mRNA
levels of AKP2, AKP3, AKP5, and AKP6 were determined
by QPCR. While no significant difference was noted in
the expression of AKP2, AKP5, and AKP6, expression of
AKP3 was significantly reduced (Fig. 1C).
Variations exist in the expression as well as activity of
IAP along the length of the ileum (Bilski et al. 2017) and
therefore, expression of IAP transgene was also monitored
along the entire length of the ileum. Almost uniform pro-
tein expression of c-myc tagged IAP transgene was noted
along the ileum (Fig. 2A) and correspondingly no signifi-
cant difference in IAP enzyme activity was seen among
the nine segments of ileum (Fig. 2B). In contrast, there
was a gradual and significant decrease in IAP activity in
nontransgenic WT mice from proximal segment P1 to
distal segment P9. To confirm secretion of IAP into the
intestinal lumen, fecal IAP activity was measured. As
shown in Figure 2C, significantly higher IAP activity was
present in feces from IAPTg mice (5181.67  942.53 vs.
246.46  128.17, P < 0.0001). Plasma IAP activity, on the
other hand was much lower than fecal activity in WT as
well as IAPTg mice.
Since there was no significant difference in IAP expres-
sion between the 2 founder lines tested, the line in pure
C57BL/6 background was chosen for further studies.
Transgenic expression of IAP improves
WD-induced glucose intolerance
Based on our earlier observation that attenuation of WD-
induced glucose intolerance by oral supplementation with
curcumin was associated with increase in IAP activity
(Ghosh et al. 2014), intestine-specific IAPTg mice were
developed to directly test this causal relationship.
Although no significant difference in blood glucose clear-
ance was noted between WT and IAPTg mice on chow
diet (Fig. 3A), WD feeding for 16 weeks led to significant
2018 | Vol. 6 | Iss. 14 | e13790
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Figure 2. IAP is uniformly expressed along the entire length of the ileum. (A) Duodenum (D), Jejunum (J) and 1–9 equal segments of ileum
from jejunum to colon were harvested from nontransgenic (WT) and IAPTg littermates. Total protein extracts were analyzed by Western blot
analyses and representative blots are shown. Immunoreactive bands for C-terminal c-myc tag and b-actin are indicated by arrows. (B) Ileal
segments P1 through P9 harvested from nontransgenic (WT) and IAPTg littermates were used to assay for IAP enzyme activity as described
under Methods. Data are presented as Mean  SD, n = 3. *P < 0.05 compared to P1 segment. (C) Fecal and plasma IAP activity was
determined as described under “Method” and data are presented as Mean  SD, n = 4 for each genotype. *P < 0.05.
Figure 1. Villin promoter-driven intestine-specific expression of IAP. At 10 weeks of age nontransgneic (WT) and IAPTg littermates were
euthanized and RNA as well as total protein extracts were prepared from the indicated tissues. (A) Total protein extracts from indicated tissues
were analyzed by Western blot analyses using primary antibody to c-myc tag and b-actin. Representative blots are shown and immune-reactive
bands are indicated by arrows. (B) mRNA levels of chimeric IAP were quantified by QPCR as described under Methods and IAP mRNA copy
number was calculated. (C) Total RNA from ileum was used to determine the mRNA levels of indicated endogenous IAP isoforms by QPCR.
Data are expressed as Mean  SD, n = 3. *P < 0.05.
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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intolerance in WT mice (Fig. 3B and C, note the signifi-
cant difference in AUC). Consistent with increased
expression and activity of IAP in the intestine of IAPTg
mice, WD-induced glucose intolerance was significantly
attenuated in these mice.
WD-induced changes in plasma lipids are thought to
underlie downstream metabolic changes and to examine
whether transgenic expression of IAP dependent changes
in plasma lipid levels underlie the observed improvement
of glucose tolerance, total plasma cholesterol, and triglyc-
eride levels were monitored. As shown in Figure 4A,
whereas there was a diet-dependent increase in plasma
cholesterol levels, there was no difference between the two
genotypes either on chow diet or WD. WD feeding did
not significantly affect the plasma triglyceride levels in
either genotype. These data indicate that intestine-specific
transgenic expression of IAP does not affect plasma lipid
levels. It should be noted that these mice are on C57BL/6
background and not on a hyperlipidemic (LDLR-/- or
ApoE-/-) background.
Transgenic expression of IAP improved
intestinal barrier function
We have earlier demonstrated disruption of WD-induced
intestinal barrier function and proposed its causal role in
the development of WD-induced metabolic changes. The
effects of IAP over expression in the ileum on changes in
intestinal permeability as a result of WD feeding were
directly evaluated by monitoring the translocation of
orally administered 4 kDa FITC-dextran. WD feeding led
to >50% increase in plasma FITC levels but this increase
was significantly reduced in IAPTg mice (Fig. 5A)
demonstrating an improvement in intestinal permeability.
Figure 3. Transgenic expression of IAP improves WD-induced glucose intolerance. Nontransgenic wild-type (WT) and IAPTg littermates of both
sexes were either fed chow or WD for 16 weeks. After an overnight fast, intraperitoneal glucose tolerance tests were performed. Blood
glucose levels over time for chow fed (A) or WD fed (B) mice are shown (Mean  SD, n = 6). (C) Area under the curve (AUC) for the plots for
individual mice included in the mean data shown in (A and B) were determined and Mean  SD, n = 6 of AUC are shown. *P < 0.05.
Figure 4. Transgenic expression of IAP does not significantly alter
plasma lipid profiles: Nontransgenic wild-type (WT) and IAPTg
littermates of both sexes were either fed chow or WD for
16 weeks. After an overnight fast, mice were euthanized and blood
was collected by cardiac puncture. Plasma total cholesterol (A) and
triglycerides (B) were determined as described under methods. Data
(Mean  SD, n = 6) are shown.
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Inappropriate upregulation of zonulin secretion from
the intestinal epithelial cells into the lumen increases
paracellular permeability (Fasano et al. 2000; El Asmar
et al. 2002) and fecal levels of Zonulin are used as a clini-
cal measure of intestinal permeability. Therefore, fecal
zonulin levels were monitored and as shown in Figure 5B,
compared to WT mice, reduced levels of fecal zonulin
was seen in IAPTg mice although this decrease reached
statistical significance only in the WD fed group (likely
due to greater variation in chow fed WT group).
Nonetheless, taken together these data indicate improved
intestinal barrier function in IAPTg mice. Consistently,
plasma LPS as well as IL-6 levels were lower in WD-fed
IAPTg compared to WT controls although these differ-
ences did not reach statistical significance (Fig. 5C).
Transgenic expression of IAP improved
intestinal inflammation
Disruption of the different layers of the intestinal barrier
leads to increase in systemic as well as intestinal inflam-
mation. To assess the effects of increased IAP expression
on intestinal inflammation, the number and phenotype of
intestinal macrophages was evaluated. As shown in
Figure 6, while there was no significant difference in the
number of total leukocytes or macrophages in ileum
(Panel A), significantly lower percentage of macrophages
were Ly6C-Hi or polarized toward a proinflammatory
phenotype in IAPTg mice (Panel B) suggestive of lower
intestinal inflammation in these mice.
Discussion
On the basis of the observed WD-induced reduction in
intestinal IAP and subsequent increase in intestinal per-
meability leading to glucose intolerance, in this study we
sought to examine the effects of intestine-specific trans-
genic overexpression of IAP. We report the successful
development of intestine-specific IAP transgenic mice
with uniform expression and activity of human chimeric
IAP along the intestine. Significant increase in fecal IAP
activity confirmed the secretion of IAP into the lumen of
the intestine. This targeted increase in IAP activity led to
improved intestinal barrier function and attenuation of
WD-induced increase in intestinal permeability. More
importantly, WD-induced glucose intolerance was signifi-
cantly attenuated in IAPTg mice providing direct evidence
for a causal role of WD-induced reduction in intestinal
IAP in the development of glucose intolerance.
While effects of WD on the induction of gut dysbiosis
are extensively investigated, recent studies including the
ones from our laboratory, have demonstrated the causa-
tive role of WD-induced increase in intestinal permeabil-
ity and resulting increase in the translocation of luminal
LPS (or endotoxemia) in the development of metabolic
diseases. WD not only causes local intestinal
Figure 5. Transgenic expression of IAP improves intestinal barrier function: Nontransgenic wild-type (WT) and IAPTg littermates of both sexes
were either fed chow or WD for 16 weeks. (A) After an overnight fast, mice were gavaged with FITC-dextran and euthanized after 4 h. Plasma
FITC levels were measured as described under methods. Data (Mean  SD, n = 6) are presented as percent increase in plasma FITC levels by
WD feeding. (B) Feces from individual mice were collected over a period of 48 h and fecal zonulin levels were determined. Data (Mean  SD,
n = 6) are presented as ng/g of dried feces. (C) Plasma LPS (EU/mL) and IL-6 (ng/mL) levels were determined as described under “Methods”
and Data are presented as Mean  SD, n = 4 for each genotype. *P < 0.05.
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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inflammation (Ding et al. 2010) but excess chylomicron
formation during WD feeding facilitates the translocation
of luminal LPS, internalized by the intestinal epithelial
cells from the apical side, to systemic circulation (Ghoshal
et al. 2009). This local and systemic inflammation lead to
overexpression of proinflammatory cytokines (Park et al.
2007) that increase gut permeability (Bruewer et al. 2003)
and further increase in LPS translocation (Cani et al.
2008) leading to a vicious cycle of metabolic endotoxemia
that leads to chronic inflammatory state critical to the
development of metabolic diseases (Moreira et al. 2012).
Consistently, patients with obesity, diabetes, CVD, and
NAFLD have higher circulating LPS levels than healthy
individuals (Creely et al. 2007; Thuy et al. 2008; Pussinen
et al. 2011) These observations underscore the importance
of improving intestinal barrier function and/or reducing
the levels of active LPS. IAP, secreted by the intestinal
epithelial cells, is appropriately positioned to facilitate
both these processes. In addition to dephosphorylation of
LPS, IAP is also thought to attenuate inflammatory sig-
naling by other bacterial components such as CpG DNA
and flagellin without direct effects on bacteria (Chen
et al. 2010). Consistently, reduced polarization of intesti-
nal macrophages to proinflammatory Ly6C-Hi phenotype
was seen in IAPTg mice. Furthermore, the observed
reduction in FITC-dextran translocation seen in IAPTg
mice demonstrates that intestine-specific transgenic
expression of human chimeric IAP indeed improves
intestinal barrier function establishing the causal link
between IAP expression and intestinal permeability.
Intestinal barrier function and paracellular transport is
maintained/regulated by appropriate expression and orga-
nization of tight junctions consisting of multiple proteins
(e.g., membrane spanning proteins occludins or claudins
and other tight junction proteins such as ZO-1, ZO-2,
and ZO-3) as well as organization/contractility of
the actin microfilaments (Anderson 2001; Tsukita et al.
2001). Furthermore, these tight junctions open and close
in response to a variety of stimuli including dietary com-
ponents and luminal microbial factors. One such pathway
that is relevant to intestinal barrier dysfunction and the
disease process is the zonulin pathway. Analogous to bac-
terial toxin (zonula occludens), inappropriate upregula-
tion of zonulin secretion from the intestinal epithelial
cells into the lumen increases paracellular permeability
(Fasano et al. 2000; El Asmar et al. 2002) and fecal levels
of Zonulin are used as a clinical measure of intestinal per-
meability. Data presented herein show that transgenic
expression of IAP attenuates WD-induced increase in
fecal zonulin providing another likely mechanism by
which IAP could modulates intestinal barrier function in
addition to reduces luminal LPS or LPS-mediated inflam-
matory changes in the intestinal epithelial cell layer.
While certain bacteria (El Asmar et al. 2002) and gliadin
(Clemente et al. 2003) are recognized as the two major
triggers for zonulin release, the mechanism by which IAP
affects the zonulin pathway remains to be established.
While the causal role of the disruption of intestinal
barrier function in the development of inflammatory
bowel disease is well established (Lee et al. 2018), its role
is also being causally associated with the development of
multiple diseases including diabetes, NAFLD (Wang et al.
2018), COPD (Sprooten et al. 2018), Parkinson’s disease
(Schwiertz et al. 2018), multiple sclerosis (Buscarinu et al.
2018). Data presented herein show that transgenic expres-
sion of IAP led to improved intestinal barrier function as
well as attenuation of WD-induced glucose intolerance.
These data are not only consistent with the fact that mice
deficient in IAP develop Type 2 diabetes (Kaliannan et al.
2013) and reduced levels of fecal IAP is seen in diabetic
subjects (Lassenius et al. 2017) but also with our earlier
demonstration of improved glucose tolerance by oral sup-
plementation with curcumin that increased IAP activity
(Ghosh et al. 2014). It is also noteworthy that other inter-
ventions such as berberine supplementation also
improved the diabetic status by enhancing the intestinal
Figure 6. Transgenic expression of IAP improves intestinal inflammation: Nontransgenic wild-type (WT) and IAPTg littermates of both sexes
were fed WD for 16 weeks. Single cell preparations of ileum were prepared and stained for leukocytes and macrophages as described under
“Methods” and analyzed by flow cytometry. (A) Total number of CD45 + leukocytes and CD11b+ macrophages per mg of tissue are shown
(Mean  SD, n = 6). (B) Percentage of Ly6C-Hi and Ly6C-Lo within the total CD45 + CD11b+Ly6C+ population was determined and data are
presented as Mean  SD, n = 6. *P < 0.05.
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barrier function (Shan et al. 2013) underscoring the
importance of IAP as potential therapeutic strategy to
improve intestinal barrier function.
Exogenous supplementation with IAP thus represents a
viable strategy for decreasing the development of diseases
linked to increase in intestinal permeability and systemic
translocation of bacteria/bacterial products. Instability and
loss of activity of IAP at pH < 5.0, precludes its oral
administration without specific enteric formulation to cir-
cumvent gastric inactivation. Consistently, Tuin et al.
(2009) reported attenuation of DSS-induced colitis in rats
by supplementation with IAP given as enteric-coated
tablets that prevents dissolution in the stomach and inacti-
vation of acid labile IAP. To bypass gastric inactivation,
Lukas et al. (2010) administered 30,000U of alkaline phos-
phatase intraduodenally and reported successful treatment
of patients with severe ulcerative colitis. The current study
along with demonstrated success with administration of
exogenous IAP pave the way for developing appropriate
platforms for intestinal delivery of active IAP enzyme
(withstanding the low gastric pH-dependent inactivation/
degradation) as a novel and simple/noninvasive strategy for
attenuation of WD-induced metabolic changes including
glucose intolerance and diabetes.
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